KOD News and Press, Kodiak Sciences Inc

2026-02-23 13:40:26 ET On February 17, 2026, Baker Bros. Advisors LP disclosed a buy of 2,608,696 shares of Kodiak Sciences (NASDAQ:KOD) , an estimated $53.42 million trade based on quarterly average pricing. According to its SEC filing dated February 17, 2026, Baker Bros. A...

2026-02-19 17:34:01 ET On February 17, 2026, Connecticut-based Braidwell disclosed a new position in Kodiak Sciences (NASDAQ:KOD) , acquiring 2,072,788 shares in a trade estimated at $57.96 million. Braidwell LP reported a new holding in Kodiak Sciences, acquiring 2,072,788 shar...

Final APEX Phase 1b Clinical Results for Kodiak's KSI-101 in Macular Edema Secondary to Inflammation to be Presented at Angiogenesis 2026 PR Newswire PALO ALTO, Calif. , Feb. 4, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biote...

2026-02-03 07:48:12 ET Shares of vision loss treatment concern Kodiak Sciences Inc. ( KOD ) have staged a massive rally off of their 52-week low set in April 2025, thanks to encouraging data from asset KSI-101 and its competitor. The IL-6/VEGF bispecific protein produced solid v...

2026-01-12 20:45:58 ET Kodiak Sciences Inc. (KOD) 44th Annual J.P. Morgan Healthcare Conference January 12, 2026 4:30 PM EST... Read the full article on Seeking Alpha For further details see: Kodiak Sciences Inc. (KOD) Presents at 44th Annual J.P. Morgan Healthcare Conferenc...

2026-01-09 15:00:43 ET More on the markets Don't Fight The Trump QE 2026 Forecast: Don't Fight The Fed Until It's Dead Is The Infamous 'Wall Of Worry' Finally Crumbling? AllianceBernstein sees steady growth in 2026, but flags rising volatility and policy risk...

Kodiak Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference PR Newswire PALO ALTO, Calif. , Jan. 7, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and comm...

2026-01-07 01:15:06 ET UBS analyst issues BUY recommendation for KOD on January 7, 2026 05:44AM ET. The previous analyst recommendation was Neutral. KOD was trading at $25.05 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst...

Kodiak Sciences Announces Closing of $184 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares PR Newswire PALO ALTO, Calif. , Dec. 18, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial re...

2025-12-17 10:16:08 ET Kodiak Sciences Inc. (NASDAQ: KOD) is one of today’s top gainers. The company’s shares have moved 15.17% on the day to $27.79. Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics...